Stock Track | Insilico Medicine Soars 8.47% Intraday on AACR Pan-KRAS Inhibitor Research Presentation

Stock Track04-20

Insilico Medicine's stock surged 8.47% during intraday trading on Monday, reflecting strong investor interest in the company's latest research developments.

The sharp rise follows the company's presentation of research on its oral pan-KRAS inhibitor ISM6166 at the American Association for Cancer Research (AACR) annual meeting. Pan-KRAS inhibitors represent a breakthrough direction in KRAS-targeted therapy as they can simultaneously target multiple oncogenic KRAS variants and aim to overcome drug resistance caused by compensatory wild-type RAS activation observed clinically.

Insilico Medicine leverages its generative AI platform to address the complex challenge of balancing pocket conformation and polarity differences across different KRAS mutants, a task considered difficult through traditional medicinal chemistry approaches. The company's presentation was selected alongside global peers including Amgen and Chugai Pharmaceutical, boosting market sentiment around its research capabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148602503?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148602503","market":"hk","top_or_hot":-1,"title":"Stock Track | Insilico Medicine Soars 8.47% Intraday on AACR Pan-KRAS Inhibitor Research Presentation","media":"Stock Track","content":"<p>Insilico Medicine's stock surged 8.47% during intraday trading on Monday, reflecting strong investor interest in the company's latest research developments.</p><p>The sharp rise follows the company's presentation of research on its oral pan-KRAS inhibitor ISM6166 at the American Association for Cancer Research (AACR) annual meeting. Pan-KRAS inhibitors represent a breakthrough direction in KRAS-targeted therapy as they can simultaneously target multiple oncogenic KRAS variants and aim to overcome drug resistance caused by compensatory wild-type RAS activation observed clinically.</p><p>Insilico Medicine leverages its generative AI platform to address the complex challenge of balancing pocket conformation and polarity differences across different KRAS mutants, a task considered difficult through traditional medicinal chemistry approaches. The company's presentation was selected alongside global peers including Amgen and Chugai Pharmaceutical, boosting market sentiment around its research capabilities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insilico Medicine Soars 8.47% Intraday on AACR Pan-KRAS Inhibitor Research Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insilico Medicine Soars 8.47% Intraday on AACR Pan-KRAS Inhibitor Research Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-20 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine's stock surged 8.47% during intraday trading on Monday, reflecting strong investor interest in the company's latest research developments.</p><p>The sharp rise follows the company's presentation of research on its oral pan-KRAS inhibitor ISM6166 at the American Association for Cancer Research (AACR) annual meeting. Pan-KRAS inhibitors represent a breakthrough direction in KRAS-targeted therapy as they can simultaneously target multiple oncogenic KRAS variants and aim to overcome drug resistance caused by compensatory wild-type RAS activation observed clinically.</p><p>Insilico Medicine leverages its generative AI platform to address the complex challenge of balancing pocket conformation and polarity differences across different KRAS mutants, a task considered difficult through traditional medicinal chemistry approaches. The company's presentation was selected alongside global peers including Amgen and Chugai Pharmaceutical, boosting market sentiment around its research capabilities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1148602503","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148602503","pubTimestamp":1776649307,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insilico Medicine's stock surged 8.47% during intraday trading on Monday, reflecting strong investor interest in the company's latest research developments.The sharp rise follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|Insilico Medicine盘中大涨8.47%AACR泛KRAS抑制剂研究演示","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine's stock surged 8.47% during intraday trading on Monday, reflecting strong investor interest in the company's latest research developments.The sharp rise follows the company's presentation of research on its oral pan-KRAS inhibitor ISM6166 at the American Association for Cancer Research (AACR) annual meeting. Pan-KRAS inhibitors represent a breakthrough direction in KRAS-targeted therapy as they can simultaneously target multiple oncogenic KRAS variants and aim to overcome drug resistance caused by compensatory wild-type RAS activation observed clinically.Insilico Medicine leverages its generative AI platform to address the complex challenge of balancing pocket conformation and polarity differences across different KRAS mutants, a task considered difficult through traditional medicinal chemistry approaches. The company's presentation was selected alongside global peers including Amgen and Chugai Pharmaceutical, boosting market sentiment around its research capabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148602503","isCrawlerRequest":true}